KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Total Current Liabilities (2016 - 2026)

Biocryst Pharmaceuticals filings provide 16 years of Total Current Liabilities readings, the most recent being $196.1 million for Q4 2025.

  • On a quarterly basis, Total Current Liabilities rose 22.25% to $196.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $196.1 million, a 22.25% increase, with the full-year FY2025 number at $196.1 million, up 22.25% from a year prior.
  • Total Current Liabilities hit $196.1 million in Q4 2025 for Biocryst Pharmaceuticals, up from $190.2 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $196.1 million in Q4 2025 to a low of $81.0 million in Q1 2022.
  • Median Total Current Liabilities over the past 5 years was $117.8 million (2021), compared with a mean of $125.2 million.
  • Biggest five-year swings in Total Current Liabilities: tumbled 38.9% in 2022 and later soared 69.2% in 2024.
  • Biocryst Pharmaceuticals' Total Current Liabilities stood at $103.7 million in 2021, then increased by 1.73% to $105.5 million in 2022, then surged by 42.15% to $150.0 million in 2023, then grew by 6.93% to $160.4 million in 2024, then rose by 22.25% to $196.1 million in 2025.
  • The last three reported values for Total Current Liabilities were $196.1 million (Q4 2025), $190.2 million (Q3 2025), and $177.2 million (Q2 2025) per Business Quant data.